↓ Skip to main content
What is this page? Embed badge

Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors …

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2025
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news
1 news outlet
twitter
11 X users
bluesky
1 Bluesky user

Readers on

mendeley
4 Mendeley
So far, Altmetric has seen 1 Bluesky post from an account with 119 followers.
This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.

Login to access the Sentiment Analysis related to this output.